Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drugs Metabolism-Related Genes Variants Impact on Anthracycline-Based Chemotherapy Induced Subclinical Cardiotoxicity in Breast Cancer Patients

25 Apr 2025

Abstract excerpt

Breast cancer is the most common cancer in women worldwide. Anthracyclines (doxorubicin, epirubicin, daunorubicin, idarubicin) are among the most used drugs for the treatment of breast cancer. Unfortunately, anthracyclines cause cardiotoxicity, which is a limiting factor for its use, and the lifetime cumulative dose of anthracyclines is the major risk factor for cardiotoxicity. In our study, we focused on acute...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related cognitive impairment studies
Share to Cancer Treatment and Pharmacology
Share to Chemotherapy-induced cardiotoxicity and mitigation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40362292
DOI: 10.3390/ijms26094051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drugs Metabolism-Related Genes Variants Impact on Anthracycline-Based Chemotherapy Induced Subclinical Cardiotoxicity in Breast Cancer PatientsPMID 40362292Read ↗

Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and EfficacySemantic proximity Read ↗

Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer.Semantic proximity Read ↗

Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.Semantic proximity Read ↗

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patientsSemantic proximity Read ↗

Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study.Semantic proximity Read ↗

Genetic factors in the pathogenesis of cardio-oncology.Semantic proximity Read ↗

HFE Gene Variants' Impact on Anthracycline-Based Chemotherapy-Induced Subclinical Cardiotoxicity.Semantic proximity Read ↗

The Impact of Polymorphisms in ATP-Binding Cassette Transporter Genes on Anthracycline-Induced Early Cardiotoxicity in Patients with Breast CancerSemantic proximity Read ↗

Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) RegimenSemantic proximity Read ↗

Risk factors for anthracycline-associated cardiotoxicity.Semantic proximity Read ↗

Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.Semantic proximity Read ↗

Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.